Table 1.
Clinical trials of nanosystem therapeutic strategies for PDAC (obtained from https://clinicaltrials.gov/, accessed on 1 October 2022).
| Nanosystems | Nanomaterials | Study Design | Identifier |
|---|---|---|---|
| Nano-SMART: AGuIX gadolinium-based NPs with radiotherapy | NPs | Phase I/II trial | NCT04789486 |
| Hafnium oxide-containing NPs NBTXR3 with radiation therapy | NPs | Phase I study | NCT04484909 |
| AA NABPLAGEM: ascorbic acid, NP paclitaxel protein-bound, cisplatin, and GEM | NPs | Phase Ib/II trial | NCT03410030 |
| SNB-101: nano-particle formulation of SN-38, the active metabolite of irinotecan (CPT-11) | NPs | Phase I study | NCT04640480 |
| IMX-110: NPs encapsulating a Stat3/NF-kB/poly-tyrosine kinase inhibitor and low-dose doxorubicin | NPs | Phase I/IIa trial | NCT03382340 |
| BIND-014: docetaxel NPs for injectable suspension | NPs | Phase I study | NCT01300533 |
| CALAA-01: a targeted nanocomplex that contains anti-R2 siRNA | NPs | Phase I study | NCT00689065 |
| CYT-6091: a PEGylated colloidal gold-rhTNF nanomedicine | Colloidal AuNPs | Phase I study | NCT00356980 |
| Paclitaxel liposome and S-1 | Liposome | Single-arm, prospective study | NCT04217096 |
| Mitoxantrone hydrochloride liposome | Liposome | Phase II study | NCT05100329 |
| Docetaxel and liposomal doxorubicin chemotherapy with enoxaparin | Liposome | Phase II trial | NCT00426127 |
| PanDox: thermosensitive liposomal doxorubicin | Liposome | Phase I study | NCT04852367 |
| Aroplatin (liposomal NDDP, L-NDDP) and GEM | Liposome | Phase I/II study | NCT00081549 |
| MM-398 (nanoliposomal irinotecan, Nal-IRI) and Ferumoxytol | Liposome | Phase I study | NCT01770353 |
| Genexol-PM (cremophor EL-free polymeric micelle of paclitaxel) and GEM | Micelle | Phase I/II trial | NCT00882973 |
| NC-6004 (a novel micellar cisplatin formulation) and GEM | Micelle | Phase III study | NCT02043288 |